02142.HK
HBM Holdings Limited
HKSE · Healthcare · Biotechnology · CN
HKD 14.72
−2.52%Year over year
Reported trailing growth
- Revenue
- +93.3%
- EBITDA
- +580.3%
- EBIT
- +481.1%
- EPS
- +360.2%
- Free cash flow
- +258.7%
- Operating cash flow
- +330.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +57.3%
- EBITDA
- +63.4%
- EBIT
- +92.3%
- Net income
- +100.3%
- EPS
- +97.7%
- Free cash flow
- +128.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026